John P Feighner

Title: John P. Feighner: Innovator in Peptide Therapeutics

Introduction

John P. Feighner, a prominent inventor based in La Jolla, California, has made significant contributions to the field of biomedical research. He is best known for his innovative work on therapeutic uses of peptides, specifically targeted at treating neurological and psychiatric disorders. With one patent to his name, Feighner has cemented his place as a notable figure in the realm of peptide therapeutics.

Latest Patents

Feighner’s patent, titled "Therapeutic uses of tri-, tetra-, penta-, and polypeptides," discloses novel uses of certain peptides for the treatment of patients suffering from various neurological and psychiatric conditions. The patent encompasses the tripeptide hormone MIF and its modified derivatives. These modifications include alterations to amino terminus residues, carboxyl terminus residues, and internal residues—allowing for the addition and substitution of amino acid residues along with modifications to peptide bonds and functional side groups. This innovative approach enables the tri-, tetra-, penta-, peptides, and polypeptides to be utilized alone or in conjunction with other agents, enhancing treatment for individuals with physiological, psychosomatic, neurological, or psychiatric disorders.

Career Highlights

John P. Feighner is affiliated with Innapharma, Inc., where his research focuses on advancing therapeutic applications of peptides. His career reflects a strong commitment to improving patient outcomes through innovative pharmaceutical solutions. With a clear focus on neurological and psychiatric health, Feighner's work is both groundbreaking and essential in contemporary medicine.

Collaborations

Feighner has collaborated with notable colleagues in his field, including Henry B. Abajian and Joseph J. Hlavka. These partnerships have facilitated the sharing of ideas and advancements, contributing to the successful development of therapeutic modalities that address complex health challenges.

Conclusion

John P. Feighner’s contributions to the field of peptide therapeutics exemplify the impact of innovation in medicine. His singular patent underscores the potential for novel therapeutic approaches to address pressing medical needs, particularly in neurological and psychiatric disorders. As research continues to evolve, Feighner remains a key figure in the pursuit of effective treatments, paving the way for future advancements in the pharmaceutical industry.